Context

Celyad is a Belgian CAR-T cell therapy biopharmaceutical company listed on Nasdaq, Euronext Brussels and Euronext Paris.

By optimizing each element of CAR-T constructs, the company is focused on developing the next wave of CAR-Ts to address the limitations of current CAR-T therapies and pursues both autologous and allogeneic approaches.

The lead candidate, CYAD-01, a CAR-T therapy leveraging the natural killer receptor NKG2D, is being developed for the treatment of hematologic and solid tumors and in the phase I/II THINK trial, activity has been observed in several AML patients (including one complete response) and in patients with CRC and ovarian cancer.

The company holds a strong intellectual property portfolio that allows collaboration with world-class pharma companies.

Company sought additional funds to further finance its R&D effort and general corporate purposes.

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad’s Natural Killer Receptor based T-Cell (NKR-T) platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase 1 clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers including five solid tumors (colorectal, ovarian, bladder, triple-negative breast and pancreatic cancers) and two hematological tumors (acute myeloid leukemia and multiple myeloma). Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and Boston, Massachusetts. Celyad’s ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the NASDAQ Global Market, all under the ticker symbol CYAD.

Discover Celyad

Olivier Garnier

Investment Banking

Dr. Anne Moore

Investment Banking

Pierre Sertour

Investment Banking

Pierre Sertour photo

Pierre Kiecolt-Wahl

Investment Banking

Jean de Pracomtal

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center